/
DCF Valuation
Base-case fair value
$3.27
Intrinsic $4.36 · 25% MOS
Current price: $14.23
Base-case summary
Our base-case DCF for Anika Therapeutics, Inc. (ANIK) projects 10 years of free cash flow growth at 2.0% for years 1–5 and 1.0% for years 6–10, anchored to a default 8% growth assumption, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $1M in trailing free cash flow, this produces an intrinsic value of $4.36 per share. A 25% safety margin gives a fair value of $3.27, suggesting the stock is currently 77% overvalued against the $14.23 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$1M
Cash & equivalents
$67M
Total debt
$26M
Shares outstanding
14M